Importantly, the natural antagonist follistatin, which normally regulates Activin A activity, is insufficient to counteract its overexpression in IPF, highlighting a critical imbalance in regulatory mechanisms [17,18]. The gene discussed is FST; the disease is idiopathic pulmonary fibrosis.